Kevin R. Lynch
Founder at SphynKx Therapeutics LLC
Kevin R. Lynch active positions
Companies | Position | Start | End |
---|---|---|---|
University of Virginia | Corporate Officer/Principal | - | - |
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Chief Tech/Sci/R&D Officer | 2009-12-31 | - |
Founder | 2009-12-31 | - | |
The University of Virginia School of Medicine | Director/Board Member | - | - |
Career history of Kevin R. Lynch
Former positions of Kevin R. Lynch
Companies | Position | Start | End |
---|---|---|---|
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Director/Board Member | - | 2010-01-27 |
Founder | - | 2013-07-08 | |
Corporate Officer/Principal | 2010-01-27 | 2013-07-08 |
Training of Kevin R. Lynch
University of Rhode Island | Doctorate Degree |
Statistics
International
United States | 5 |
2 |
Operational
Director/Board Member | 2 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sectoral
Consumer Services | 4 |
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Catena Pharmaceuticals, Inc.
Catena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC. | Health Technology |
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
- Stock Market
- Insiders
- Kevin R. Lynch
- Experience